It would be useful to define expression at the mRNA and protein level of specific Hippo components, both in isolated microglia from control and AD patient brains, and in microglial cell models; in particular, studying this in hiPSC-derived microglia from control and AD patients with known mutations (e.g., APP) would allow for temporal analysis of Hippo/YAP component expression and correlation with cellular changes or pathology. Here, APP is linked to Alzheimer disease.